United States trade policy has exposed the Swiss pharmaceutical industry to a period of upheaval, according to Interpharma, which represents Switzerland's research-based pharma firms. +Get the most important news from Switzerland in your inbox Switzerland is currently standing at a crossroads, said Interpharma president Jörg-Michael Rupp stated at the association’s annual media conference. + How pharma became Switzerland's Achilles heel in US trade talks The landscape for the pharmaceutical industry in Switzerland has fundamentally changed, and competition in the rest of the world is becoming increasingly fierce. "While we are not yet lagging behind the competition, we are gradually losing our leading position,” said Rupp. Speakers, including Interpharma CEO René Buholzer, all emphasised geopolitical developments and new international rules of the game. They stressed that the country's competitiveness, innovative strength, and attractiveness are all being put to the test.
